Access to Study Data. Subject to the provisions of this Article 7, each Party shall have access to all Study Data (including de-identified patient records) as and to the extent allowed in Trial Site agreements (which agreements [***]). Olema shall make such Study Data in its possession available to Novartis on a [***] basis within a reasonable period of time, but not to exceed [***], after [***].
Appears in 2 contracts
Sources: Clinical Collaboration and Supply Agreement (Olema Pharmaceuticals, Inc.), Clinical Collaboration and Supply Agreement (Olema Pharmaceuticals, Inc.)